Maltase-glucoamylase (MGAM) (MGAM)

Maltase-glucoamylase (MGAM) is a key enzyme complex anchored to the brush border membrane of the small intestine (UniProt: P50406). It is responsible for the final step of starch digestion, specifically the hydrolysis of alpha-1,4-glycosidic linkages in maltose and malto-oligosaccharides to release free glucose (PubMed: 12675937). This enzyme is a member of the glycosyl hydrolase family 31 and works alongside sucrase-isomaltase to ensure complete carbohydrate breakdown (NCBI Gene: 4266). Clinically, MGAM is a primary target for alpha-glucosidase inhibitors like acarbose and miglitol, which are used to manage type 2 diabetes by slowing glucose absorption and reducing postprandial hyperglycemia (StatPearls: Alpha-Glucosidase Inhibitors). By competitively inhibiting MGAM, these drugs prevent rapid spikes in blood sugar, though they may cause gastrointestinal side effects due to the fermentation of undigested sugars in the large intestine (PubChem: CID 41774). Research into MGAM also explores its role in obesity and other metabolic disorders related to carbohydrate processing.

Other names

Intestinal maltaseGlucoamylaseAlpha-glucosidaseGlucan 1,4-alpha-glucosidaseMGAMMaltase-glucoamylase, intestinal

Competitive inhibition of the alpha-glucosidase activity of the MGAM enzyme complex in the brush border of the small intestine, which delays the hydrolysis of oligosaccharides and disaccharides into glucose, thereby slowing glucose absorption into the systemic circulation (StatPearls: Alpha-Glucosidase Inhibitors).